人 PD-L1 蛋白｜Human PD-L1 Protein, His tag
- PME100480
- DIMA BIOTECH
- 湖北省武汉市
- 现货
- 按需定制
- 600 - 3380
- 2022-12-22 09:12:12
缔码生物科技（武汉）有限公司
一键申请试用
咨询
加入意向单
联系方式
保存条件：
Store at -80°C for 12 months (Avoid repeated freezing and thawing)
保质期：
12 months
英文名：
Human PD-L1 Protein, His tag
数量：
现货供应
供应商：
DIMA BIOTECH
CAS号：
//
规格：
100 μg/50 μg/10 μg
规格： 100 μg 产品价格： ￥3380.0 规格： 50 μg 产品价格： ￥2350.0 规格： 10 μg 产品价格： ￥600.0
Catalog Number PME100480 Description Recombinant human PD-L1 protein with C-terminal 6×His tag Synonyms PD-L1, CD274, B7-H1, PDCD1L1, PDCD1LG1 Expression Host HEK293 Tag C-6×His tag Molecular Weight The protein has a predicted molecular mass of 26.0 kDa after removal of the signal peptide.The apparent molecular mass of PDL1-His is approximately 33-35 kDa due to glycosylation Purity The purity of the protein is greater than 95% as determined by SDS-PAGE and Coomassie blue staining Buffer Lyophilized from sterile PBS, pH 7.4. Normally 5 % - 8 % trehalose is added as protectants before lyophilization Background This gene encodes an immune inhibitory receptor ligand that is expressed by hematopoietic and non-hematopoietic cells, such as T cells and B cells and various types of tumor cells. The encoded protein is a type I transmembrane protein that has immunoglobulin V-like and C-like domains. Interaction of this ligand with its receptor inhibits T-cell activation and cytokine production. During infection or inflammation of normal tissue, this interaction is important for preventing autoimmunity by maintaining homeostasis of the immune response. In tumor microenvironments, this interaction provides an immune escape for tumor cells through cytotoxic T-cell inactivation. Expression of this gene in tumor cells is considered to be prognostic in many types of human malignancies, including colon cancer and renal cell carcinoma. Alternative splicing results in multiple transcript variants
Molecular Characterization
Figure 1. Human PD-L1 Protein, His Tag on SDS-PAGE under reducing condition.
缔码生物科技有限公司是一个专注于肿瘤免疫产品和服务的重组单克隆抗体研发公司。我们的总部位于江苏苏州，研发中心在湖北武汉。公司拥有独创的DimAbTM重组单克隆抗体技术，可以获得多种属、高质量的单克隆抗体。公司研发团队具备多年的单克隆抗体开发经验，并获得业界广泛认可。公司致力于肿瘤免疫靶标单克隆抗体的研发和生产，为全球的科学研究、临床诊断和药物研发提供全方位的解决方案。 公司的企业文化是诚信，务实，创新，专注。公司的使命是应用先进的生物技术为癌症的诊断和治疗提供全新有效的解决方案。
温馨提示：不可用于临床治疗。
